Free Trial

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics logo
$13.06 +0.51 (+4.06%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$13.06 +0.00 (+0.04%)
As of 10/3/2025 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dyne Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
1
Hold
2
Buy
14

Based on 17 Wall Street analysts who have issued ratings for Dyne Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 1 has given a sell rating, 2 have given a hold rating, 11 have given a buy rating, and 3 have given a strong buy rating for DYN.

Consensus Price Target

$34.07
160.85% Upside
According to the 17 analysts' twelve-month price targets for Dyne Therapeutics, the average price target is $34.07. The highest price target for DYN is $50.00, while the lowest price target for DYN is $9.00. The average price target represents a forecasted upside of 160.85% from the current price of $13.06.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for DYN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Dyne Therapeutics and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DYN Analyst Ratings Over Time

TypeCurrent Forecast
10/5/24 to 10/5/25
1 Month Ago
9/5/24 to 9/5/25
3 Months Ago
7/7/24 to 7/7/25
1 Year Ago
10/6/23 to 10/5/24
Strong Buy
3 Strong Buy rating(s)
3 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
11 Buy rating(s)
11 Buy rating(s)
13 Buy rating(s)
9 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$34.07$34.07$41.13$51.40
Forecasted Upside160.85% Upside139.57% Upside402.75% Upside57.77% Upside
Consensus RatingModerate BuyBuyBuyBuy

DYN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DYN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Dyne Therapeutics Stock vs. The Competition

TypeDyne TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.94
2.33
2.51
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside160.85% Upside1,395.17% Upside10.49% Upside
News Sentiment Rating
Positive News

See Recent DYN News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/27/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingSell (D-)
8/25/2025Raymond James Financial
4 of 5 stars
Martin Auster
Martin Auster
Not Rated
UpgradeOutperformStrong-Buy$31.00 ➝ $35.00+178.22%
8/6/2025Oppenheimer
2 of 5 stars
Lower TargetOutperform$34.00 ➝ $13.00+24.16%
7/31/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$66.00 ➝ $36.00+263.82%
7/29/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$25.00 ➝ $23.00+157.27%
7/29/2025Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$50.00 ➝ $38.00+308.16%
7/15/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetNeutral$10.00 ➝ $9.00+7.75%
7/11/2025Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
6/26/2025Jones Trading
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$30.00+187.91%
6/24/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform$13.00+27.95%
6/18/2025Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$50.00+354.63%
6/18/2025Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$46.00 ➝ $32.00+196.13%
5/9/2025HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$46.00 ➝ $38.00+235.63%
3/12/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$50.00+315.63%
3/7/2025Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSector Outperform$50.00+308.50%
2/28/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$53.00 ➝ $48.00+264.46%
12/12/2024Baird R W
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/14/2024Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOverweight$48.00 ➝ $52.00+19.16%
5/20/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$36.00 ➝ $42.00+22.77%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 01:13 AM ET.


DYN Forecast - Frequently Asked Questions

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Dyne Therapeutics is $34.07, with a high forecast of $50.00 and a low forecast of $9.00.

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last twelve months. There is currently 1 sell rating, 2 hold ratings, 11 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DYN shares.

According to analysts, Dyne Therapeutics's stock has a predicted upside of 160.85% based on their 12-month stock forecasts.

Over the previous 90 days, Dyne Therapeutics's stock had 1 upgrade by analysts.

Dyne Therapeutics has been rated by research analysts at Chardan Capital, Evercore ISI, JPMorgan Chase & Co., Oppenheimer, Raymond James Financial, Royal Bank Of Canada, Stifel Nicolaus, and Weiss Ratings in the past 90 days.

Analysts like Dyne Therapeutics more than other "medical" companies. The consensus rating for Dyne Therapeutics is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how DYN compares to other companies.


This page (NASDAQ:DYN) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners